Arcadia Biosciences (RKDA) Announces Date of Fourth-Quarter and Full-Year 2022 Financial Results and Business Highlights Conference Call

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its 2022 fourth-quarter and full-year financial and business results after market close on March 30, 2023.

The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss fourth-quarter and year-end results and the year’s key strategic achievements. Interested participants can join the conference call using the following options:

  • An audio-only webcast of the conference call will be available in the Investors section of Arcadia’s website.
  • To join the live call, please register here, and a dial-in number and unique PIN will be provided.

Following completion of the call, a recorded replay will be available on the company’s investor website.

About Arcadia Biosciences, Inc.

Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating crops to provide high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make every body feel good, inside and out. The company’s food, beverage and body care products include GoodWheat™, Zola® coconut water, ProVault™ topical pain relief and SoulSpring™ bath and body care. For more information, visit www.arcadiabio.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.08
+0.50 (0.21%)
AAPL  275.58
+2.63 (0.96%)
AMD  252.68
+4.72 (1.90%)
BAC  52.70
-0.17 (-0.32%)
GOOG  278.58
-0.54 (-0.19%)
META  611.46
+1.57 (0.26%)
MSFT  510.90
+7.61 (1.51%)
NVDA  190.03
+3.17 (1.70%)
ORCL  225.10
+7.53 (3.46%)
TSLA  409.48
+7.49 (1.86%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.